Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting
<h3>Background </h3><p dir="ltr">Priming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. </p>&l...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513542007291904 |
|---|---|
| author | Salma Younes (6424865) |
| author2 | Eleonora Nicolai (496034) Nadin Younes (4863280) Massimo Pieri (5023022) Sergio Bernardini (504056) Parveen B. Nizamuddin (14590613) Duaa W. Al-Sadeq (10976754) Hanin I. Daas (17863886) Ahmed Ismail (2671822) Hadi M. Yassine (4675846) Laith J. Abu-Raddad (9262524) Gheyath K. Nasrallah (9200525) |
| author2_role | author author author author author author author author author author author |
| author_facet | Salma Younes (6424865) Eleonora Nicolai (496034) Nadin Younes (4863280) Massimo Pieri (5023022) Sergio Bernardini (504056) Parveen B. Nizamuddin (14590613) Duaa W. Al-Sadeq (10976754) Hanin I. Daas (17863886) Ahmed Ismail (2671822) Hadi M. Yassine (4675846) Laith J. Abu-Raddad (9262524) Gheyath K. Nasrallah (9200525) |
| author_role | author |
| dc.creator.none.fl_str_mv | Salma Younes (6424865) Eleonora Nicolai (496034) Nadin Younes (4863280) Massimo Pieri (5023022) Sergio Bernardini (504056) Parveen B. Nizamuddin (14590613) Duaa W. Al-Sadeq (10976754) Hanin I. Daas (17863886) Ahmed Ismail (2671822) Hadi M. Yassine (4675846) Laith J. Abu-Raddad (9262524) Gheyath K. Nasrallah (9200525) |
| dc.date.none.fl_str_mv | 2024-10-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.vaccine.2024.06.010 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Comparable_antibody_levels_in_heterologous_and_homologous_mRNA_COVID-19_vaccination_with_superior_neutralizing_and_IgA_antibody_responses_in_mRNA_homologous_boosting/29898593 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Immunology Health sciences Public health AZD1222 (Oxford-AstraZeneca, ChAd) Homologous Heterologousm RNA vaccination Neutralizing antibody Anti-S1 IgA |
| dc.title.none.fl_str_mv | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background </h3><p dir="ltr">Priming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. </p><h3>Aim</h3><p dir="ltr">To evaluate and contrast the immunogenicity of homologous and heterologous boosting regimens. </p><h3>Method</h3><p dir="ltr">The study examined antibody responses in 1113 subjects, comprising 895 vaccine-naïve individuals across different vaccination strategies (partial, primary series, heterologous booster, homologous booster) and 218 unvaccinated, naturally infected individuals. Assessments included neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti-S-RBD IgG, and anti-S1 IgA levels. </p><h3>Results</h3><p dir="ltr">The study found mRNA vaccines to exhibit superior immunogenicity in primary series vaccination compared to ChAd, with mRNA-1273 significantly enhancing NTAbs, TAbs, anti-S-RBD IgG, and anti-S1 IgA levels (p < 0.001). Both booster types improved antibody levels beyond primary outcomes, with no significant difference in TAbs and anti-S-RBD IgG levels between regimens. However, homologous mRNA boosters significantly outperformed heterologous boosters in enhancing NTAbs and anti-S1 IgA levels, with the BNT/BNT/BNT regimen yielding particularly higher enhancements (p < 0.05). </p><h3>Conclusion</h3><p dir="ltr">The study concludes that although TAbs and anti-S-RBD IgG antibody levels are similar for both regimens, homologous mRNA boosting outperform heterologous regimen by enhancing anti-S1 IgA and neutralizing antibody levels.</p><h2>Other Information</h2><p dir="ltr">Published in: Vaccine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.vaccine.2024.06.010" target="_blank">https://dx.doi.org/10.1016/j.vaccine.2024.06.010</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_2e152652b1d90d40f1238431b43ce490 |
| identifier_str_mv | 10.1016/j.vaccine.2024.06.010 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29898593 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boostingSalma Younes (6424865)Eleonora Nicolai (496034)Nadin Younes (4863280)Massimo Pieri (5023022)Sergio Bernardini (504056)Parveen B. Nizamuddin (14590613)Duaa W. Al-Sadeq (10976754)Hanin I. Daas (17863886)Ahmed Ismail (2671822)Hadi M. Yassine (4675846)Laith J. Abu-Raddad (9262524)Gheyath K. Nasrallah (9200525)Biomedical and clinical sciencesClinical sciencesImmunologyHealth sciencesPublic healthAZD1222 (Oxford-AstraZeneca, ChAd)HomologousHeterologousmRNA vaccinationNeutralizing antibodyAnti-S1 IgA<h3>Background </h3><p dir="ltr">Priming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. </p><h3>Aim</h3><p dir="ltr">To evaluate and contrast the immunogenicity of homologous and heterologous boosting regimens. </p><h3>Method</h3><p dir="ltr">The study examined antibody responses in 1113 subjects, comprising 895 vaccine-naïve individuals across different vaccination strategies (partial, primary series, heterologous booster, homologous booster) and 218 unvaccinated, naturally infected individuals. Assessments included neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti-S-RBD IgG, and anti-S1 IgA levels. </p><h3>Results</h3><p dir="ltr">The study found mRNA vaccines to exhibit superior immunogenicity in primary series vaccination compared to ChAd, with mRNA-1273 significantly enhancing NTAbs, TAbs, anti-S-RBD IgG, and anti-S1 IgA levels (p < 0.001). Both booster types improved antibody levels beyond primary outcomes, with no significant difference in TAbs and anti-S-RBD IgG levels between regimens. However, homologous mRNA boosters significantly outperformed heterologous boosters in enhancing NTAbs and anti-S1 IgA levels, with the BNT/BNT/BNT regimen yielding particularly higher enhancements (p < 0.05). </p><h3>Conclusion</h3><p dir="ltr">The study concludes that although TAbs and anti-S-RBD IgG antibody levels are similar for both regimens, homologous mRNA boosting outperform heterologous regimen by enhancing anti-S1 IgA and neutralizing antibody levels.</p><h2>Other Information</h2><p dir="ltr">Published in: Vaccine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.vaccine.2024.06.010" target="_blank">https://dx.doi.org/10.1016/j.vaccine.2024.06.010</a></p>2024-10-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.vaccine.2024.06.010https://figshare.com/articles/journal_contribution/Comparable_antibody_levels_in_heterologous_and_homologous_mRNA_COVID-19_vaccination_with_superior_neutralizing_and_IgA_antibody_responses_in_mRNA_homologous_boosting/29898593CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/298985932024-10-01T00:00:00Z |
| spellingShingle | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting Salma Younes (6424865) Biomedical and clinical sciences Clinical sciences Immunology Health sciences Public health AZD1222 (Oxford-AstraZeneca, ChAd) Homologous Heterologousm RNA vaccination Neutralizing antibody Anti-S1 IgA |
| status_str | publishedVersion |
| title | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_full | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_fullStr | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_full_unstemmed | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_short | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| title_sort | Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting |
| topic | Biomedical and clinical sciences Clinical sciences Immunology Health sciences Public health AZD1222 (Oxford-AstraZeneca, ChAd) Homologous Heterologousm RNA vaccination Neutralizing antibody Anti-S1 IgA |